CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO)
   Google Scholar   
Citation:
J Clin Oncol vol 35 (15 suppl) abstr 8037
Meeting Instance:
ASCO 2017
Year:
2017
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, CA180820  
Corr. Author:
 
Authors:
                 
Networks:
LAPS-MA036, LAPS-NY158, NE003   
Study
CALGB-100104
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: